

U.S. Securities & Exchange Commission – Enforcement Division
Nasdaq Listing Qualifications

info@hithawk.com
www.hithawk.com

Via email

December 8, 2025

Dear Madam, dear Sir,

I am writing to express my serious concern regarding potentially fraudulent activity that may affect investors involving Anbio, a Nasdaq-listed firm trading under the symbol \$NNNN.

Summary of Concerns

This submission outlines a series of verifiable discrepancies related to Anbio's corporate operations, product integrity, physical presence, and public representations. My findings suggest the possibility of material misstatements in investor-facing disclosures and misleading claims about the scale and legitimacy of the business.

The red flags described below are binary, independently verifiable, and, if confirmed, constitute potential violations of:

- Securities Exchange Act of 1934, Section 10(b)
- Rule 10b-5 (material misrepresentations or omissions)
- Nasdaq Listing Rule 5250(b)(1) (obligation to provide accurate, material information)
- Nasdaq Listing Rule 5101 (public interest concern)

1. Privously Virtual Office Rented in Frankfurt City Center

The company originally registered at:

Friedrich-Ebert-Anlage 49 (Messeturm), 60308 Frankfurt am Main, Germany.

While the Messeturm is a reputable well-known address, it offers virtual and rented office space via company "Regus". As a serviced-office building, the address is used primarily for mail forwarding and client meeting room services. This has been confirmed during on-site visits.

Anbio does not maintain a real workspace, warehouse, lab, or administrative office.

The discrepancy between the company's claimed operational footprint and its actual corporate presence may indicate misleading statements to investors.

Evidence

- E-2.1 Nasdaq Market Activity website (<https://www.nasdaq.com/market-activity/stocks/nnnn>)
- E-2.2 Currently rented Business Center
- E-2.3 Personal statements from site visit

2. Current Non-existent Company Address in Frankfurt's Outskirts

During registration for the Nasdaq listing the company documents show that the company relocated within Frankfurt between July and November 2024, just before the IPO, to the following new and current address:

Wilhelm-Gutbrod-Str. 21B, 60437 Frankfurt am Main, Germany.

The address lies in the outskirts of Frankfurt without any notable office facilities. Further, the surrounding area is a commercial/ industrial area.

The address as stated does not exist in In municipal records, postal service verification. An on-site has confirmed that the address is invalid. No commercial or residential unit corresponding to house number "21 B" exists.

This raises concerns that the issuer has no physical operations at a location it claims in investor materials or regulatory filings.

Evidence

- E-1.1 Forms 6-K, 8A Underwriting agreement and others
- E-1.2 Nasdaq Market Activity website
- E-1.3 Goole Streetview/ other documentation
- E-1.4 Personal statements to site visits

3. Corporate Contact Line Is a Prepaid Mobile Number

The "landline" listed on Anbio's website and corporate materials for its' German office is a prepaid mobile number, not a fixed-line business connection.

This is inconsistent with a company purportedly handling medical products and diagnostics, where regulated contact and logistics infrastructure are standard.

Evidence

- E-3.1 List with mobile phone area codes.

4. Rapid Website Expansion From 3 Products to ~450 in Two Months

Timeline analysis shows that only a few months ago, Anbio's website listed four devices and 62 test kits as products.

In this short period of time the issuers product catalog expanded to approximately 450 products today.

However, 440 of these are test kits with identical packaging. Differences appear limited to a single text line, which often appears photoshopped.

Also, product images lack standard medical-device identifiers:

- o No lot numbers
- o No manufacturing dates
- o No importer information
- o No CE/IVD compliance markings where required
- o No unique packaging differentiation

This pattern is consistent with fabricated or non-existent product lines presented for commercial appearance rather than actual distribution.

Evidence

- E-4.1 <https://web.archive.org/web/20250225185940/https://www.anbio.com/>
- E-4.2 Today's products offered on the website
- E-4.3 Noticeable manipulations to the images of products
- E-4.4 Reverse image search findings

5. No Supply Chain or Manufacturing Partners, no Imprint

Attempts to confirm

- manufacturers
- distributors,
- certification bodies,
- logistics infrastructure,
- or warehouse facilities

resulted in no verifiable evidence of operations. This inconsistency raises the possibility that Anbio is misrepresenting the scale and legitimacy of its business.

6. Materiality and Potential Investor Harm

If Anbio is making inaccurate statements regarding

- its operational facilities,
- its product lines,
- its ability to generate revenue,
- or its corporate presence,

then investors may be relying on materially misleading information when valuing the issuer.

Given the pattern of indicators, Anbio may be

- a shell operation,
- misrepresenting its operations, and/ or
- misleading the market through inflated claims about product availability and commercial readiness.

Requested Action

I respectfully request that the SEC and/ or Nasdaq:

1. Verify the listed corporate address and determine whether the issuer maintains a legitimate operational facility,
2. request documentation supporting the authenticity of the claimed product catalog,
3. assess whether the issuer is in compliance with Nasdaq's ongoing listing requirements, including accurate and comprehensive disclosure,
4. review the issuer's public statements and filings for potential material misrepresentations.

Given the ease of independent verification (address, packaging, supply chain), this appears to be a low-friction, high-clarity case appropriate for preliminary regulatory review.

Sincerely.

HitHawk Research

E-1.1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission File Number: 001-42526

Anbio Biotechnology

Wilhelm Gutbrod Str 21B, 60437,
Frankfurt am Main

Corporate Information

Our principal executive offices are located at Wilhelm Gutbrod Str 21B, 60437, Frankfurt am Main, Germany. Our telephone number is +49-16-0962-47281. Our registered office in the Cayman Islands is located at the offices of Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 — 1205 Cayman Islands. Our agent for service of process in the United States is C T Corporation System, 128 Liberty Street, New York, NY 10005, +1-212-894-8940.

Investors should contact us for any inquiries through the address and telephone number of our principal executive offices.


E-1.3



E-2.1

Company Overview

Proposed Symbol	NNNN
Company Name	Anbio Biotechnology
Exchange	NASDAQ Global
Share Price	\$5.00
Employees	27 (as of 02/19/2025)
Status	Priced
Shares Offered	1600000
Offer amount	\$8,000,000
Shares Over Alloted	--
Company Address	FRIEDRICH-EBERT-ANLAGE 49 FRANKFURT AM MAIN 60308
Company Phone	4916096247281



Regus

Nach einem Standort suchen

+49 211 81997063 Kontakt

DE

Büroraum Coworking Virtuelle Büros Konferenzräume Mitgliedschaft Geschäftsadresse Telefonservice Veranstaltungsbereich Private Büros Individuelle Büros

Angebot einholen Jetzt anfragen

Galerie anzeigen

Über Messeturm.

Beindruckender Standort in einem markanten Wolkenkratzer

Genießen Sie die unvergleichliche Aussicht an einem Standort im zweithöchsten Gebäude der Europäischen Union. Beeindrucken Sie Ihre Kunden in den stilvoll eingerichteten Büroräumen im Center Messeturm, das im 9. Stockwerk des gleichnamigen majestätischen Wolkenkratzers untergebracht ist.

Entwickeln Sie in den modernen Konferenz- und Tagungsräumen neue Ideen. Die Räume bestechen mit kräftigen Farben und reichlich Licht durch die großen Fenster. Brauchen Sie eine Pause? Setzen Sie sich in der komfortablen Lounge oder entspannen Sie sich im Café. Die beliebten Restaurants am Flussufer und die Bars im benachbarten Stadtteil Gutleutviertel laden zu Besuchen mit geschäftlichen Gästen

MEHR ANZEIGEN

Ausstattung ab Me

Adresse des Gebäudes

Friedrich-Ebert-Anlage 49 Frankfurt am Main 60308

[Routenplanung \(Google\)](#)

Sie sind an diesem Standort interessiert

Wählen Sie eine der folgenden Optionen aus, um loszulegen


- Angebot einholen**
Sprechen Sie mit einem Experten, um alles über unsere Optionen und Preise zu erfahren.
- Einen Besuch vereinbaren**
Buchten Sie eine Tour in diesem Center und erfahren Sie mehr.
- Virtuelles Büro kaufen**
Beginnen Sie heute, sich eine echte Präsenz zu kaufen.

E-3.1



Vorwahl	Anbieter
0150	O2
0151	Telekom
0152	Vodafone
01529	1Global (ehemals Truphone)
0155	O2 (ehemals e-plus)
01555	1&1
01556	1&1
015678	Satellite
015679	Satellite
0157	O2 (ehemals e-plus)
01579	eSIM (ehemals simquadrat)
015888	TelcoVillage GmbH
0159	O2
0160	Telekom
0161	Telekom
0162	Vodafone
0163	O2 (ehemals e-plus)
0170	Telekom
0171	Telekom
0172	Vodafone
0173	Vodafone
0174	Vodafone
0175	Telekom
0176	O2
0177	O2 (ehemals e-plus)
0178	O2 (ehemals e-plus)
0179	O2

Die Rufnummern werden einem bestimmten Anbieter zugeteilt, können aber im Rahmen der Rufnummernmitnahme von den Kunden zu anderen Anbietern mitgenommen werden. Eine Nummer wird daher nicht notwendigerweise im angegebenen Netz betrieben.

E-4.2



E-4.3



E-4.4

